Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on transforming the treatment paradigm for people with rare metabolic disorders, particularly those related to obesity and appetite regulation
The company is dedicated to advancing its research and development efforts to create therapies that target the underlying causes of these conditions. By leveraging innovative science and its expertise in the genetic basis of obesity, Rhythm aims to develop effective treatments that improve the quality of life for patients and address significant unmet medical needs in the field of metabolic health.
Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep
